Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 10/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252245 | 1.00 | SLC6A4 (0.51) | SLC6A4DRD4DRD2GSK3BPPARG | |
| SCHEMBL18601776 | 0.85 | HTR7 (0.53) | SLC6A4DRD4DRD2GSK3BPPARG | |
| SCHEMBL6814945 | 0.85 | HTR7 (0.53) | SLC6A4DRD4DRD2GSK3BPPARG | |
| SCHEMBL318891 | 0.84 | SLC6A4 (0.51) | SLC6A4DRD4DRD2GSK3BPPARG | |
| SCHEMBL10248696 | 0.84 | SLC6A4 (0.51) | SLC6A4DRD4DRD2GSK3BPPARG | |
| SCHEMBL11256999 | 0.83 | DRD4 (0.47) | SLC6A4DRD4DRD2GSK3BPPARG | |
| SCHEMBL11257002 | 0.83 | DRD4 (0.47) | SLC6A4DRD4DRD2GSK3BPPARG | |
| SCHEMBL13147671 | 0.80 | SLC6A4 (0.47) | SLC6A4DRD4DRD2GSK3BPPARG | |
| SCHEMBL6811236 | 0.78 | TRPA1 (0.49) | SLC6A4DRD4DRD2GSK3BLMNA | |
| SCHEMBL4467279 | 0.76 | GSK3B (0.71) | SLC6A4DRD4DRD2GSK3BPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | SLC6A4 262/4885DRD4 7/4885DRD2 1/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | SLC6A4 262/4885DRD4 7/4885DRD2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.